ADRA2B agonists(Alpha-2b adrenergic receptor agonists), α2A-AR agonists(Alpha-2a adrenergic receptor agonists), α2C-AR agonists(Alpha-2c adrenergic receptor agonists)

Therapeutic Areas

Nervous System Diseases

Active Indication

Pain

Inactive Indication-

Originator Organization-

Active Organization-

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Structure

Molecular FormulaC13H11ClN2O2

InChIKeyCLOMYZFHNHFSIQ-UHFFFAOYSA-N

CAS Registry17737-65-4

Clinical Trials associated with Clonixin

NCT01421433 / Unknown statusPhase 3

Non Inferiority,Phase III,Multicentric,Double Blind,Randomized,Parallel Study,Comparing Dolamin Flex (Lysine Clonixinate+Cyclobenzaprine) and Tandrilax(Caffeine +Carisoprodol+Diclofenac+Paracetamol)in Pain Reduction in Patients With Lumbago

Non inferiority, multicentric, double blind study whose the primary objective is to compare the effectiveness of two products in pain reduction. Primary endpoint: reduction in pain average at day 7 compared to day 1(baseline), using Analogue Visual Scale (AVS) for pain evaluation. Secondary endpoint: to evaluate the products safety at the gastrointestinal system.

Start Date01 May 2012

Sponsor / Collaborator

Farmoquímica SA

[+1]

100 Clinical Results associated with Clonixin

100 Translational Medicine associated with Clonixin

100 Patents (Medical) associated with Clonixin

Literatures (Medical) associated with Clonixin

01 Jun 2022·Journal of Inorganic BiochemistryQ2 · BIOLOGY

In silico study of potential antiviral activity of copper(II) complexes with non–steroidal anti–inflammatory drugs on various SARS–CoV–2 target proteins

Q2 · BIOLOGY

Article

Author: Psomas, George ; Malis, Georgios ; Geromichalou, Elena G ; Dalezis, Panagiotis ; Trafalis, Dimitrios T ; Geromichalos, George D

In silico molecular docking studies, in vitro toxicity and in silico predictions on the biological activity profile, pharmacokinetic properties, drug-likeness, ADMET (absorption, distribution, metabolism, excretion, and toxicity) physicochemical pharmacokinetic data, and target proteins and toxicity predictions were performed on six copper(II) complexes with the non-steroidal anti-inflammatory drugs ibuprofen, loxoprofen, fenoprofen and clonixin as ligands, in order to investigate the ability of these complexes to interact with the key therapeutic target proteins of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) 3C-like cysteine main protease (3CLpro/M^pro), viral papain-like protease (PLpro), RNA-dependent RNA polymerase (RdRp), and non-structural proteins (Nsps) Nsp16-Nsp10 2'-O-methyltransferase complex, and their capacity to act as antiviral agents, contributing thus to understanding the role they can play in the context of coronavirus 2019 (COVID-19) pandemic. Cytotoxic activity against five human cancer and normal cell lines were also evaluated.

01 Nov 2021·Journal of Inorganic BiochemistryQ2 · BIOLOGY

Copper(II) complexes with non–steroidal anti–inflammatory drugs: Structural characterization, in vitro and in silico biological profile

Q2 · BIOLOGY

Article

Author: Psomas, George ; Hatzidimitriou, Antonios G ; Geromichalos, George D ; Malis, Georgios ; Geromichalou, Elena

Six novel copper(II) complexes with the non-steroidal anti-inflammatory drugs ibuprofen, loxoprofen, fenoprofen and clonixin as ligands were synthesized and characterized by diverse techniques including single-crystal X-ray crystallography. The in vitro scavenging activity of the complexes against 1,1-diphenyl-picrylhydrazyl and 2,2'-azinobis(3-ethylbenzothiazoline-6-sulfonic acid) free radicals and the ability to reduce H₂O₂ were studied in the context of the antioxidant activity studies. The complexes may interact with calf-thymus DNA via intercalation as revealed by the techniques employed. The affinity of the complexes for bovine and human serum albumins was evaluated by fluorescence emission spectroscopy and the corresponding binding constants were determined. Molecular docking simulations on the crystal structure of calf-thymus DNA, human and bovine serum albumins were also employed in order to study in silico the ability of the studied compounds to bind to these target biomacromolecules, in terms of impairment of DNA and transportation through serum albumins, to explain the observed in vitro activity and to establish a possible mechanism of action.

16 Feb 2021·Journal of Investigational Allergology and Clinical ImmunologyQ3 · MEDICINE

IgE-Mediated Hypersensitivity to Lysine Clonixinate

Q3 · MEDICINE

Article

Author: López San Martín, M G ; Villalón García, A L ; Pérez Pimiento, A ; Iglesias Cadarso, A

100 Deals associated with Clonixin

External Link

KEGG	Wiki	ATC	Drug Bank
D03555	Clonixin	N02	DB09218

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pain	-	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis